tldrdailynews.com logo

Merck's New Oral PCSK9 Inhibitor Shows Promise in Lowering Cholesterol

1 min read
Source: Merck.com
Merck's New Oral PCSK9 Inhibitor Shows Promise in Lowering Cholesterol
Photo: Merck.com
TL;DR

Merck announced promising Phase 3 trial results showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduces LDL cholesterol by over 55% with a safety profile similar to placebo, potentially offering a new oral treatment for cardiovascular disease prevention.

Topics:businesshealthcare#cardiovascular-health#enlicitide#healthcare#ldl-c-reduction#merck#phase-3-trial
Share this article
  1. Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial  Merck.com
  2. Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future  The New York Times
  3. More Drugs to Fight High Cholesterol Are Emerging  The Wall Street Journal
  4. Merck’s pill to reduce cholesterol on top of statins matches results from injectables  statnews.com
  5. Experimental daily pill may lower cholesterol in patients who don’t see enough benefit with statins alone, study finds  CNN

Want the full story? Read the original reporting

Read on Merck.com